HLA-A and prostate adenocarcinoma: Notably, neither HLA‐A*02:01 nor HLA‐A*24:02 were associated with recurrence in TCGA‐PRAD (Fig. 2A), in which the HLA allele group HLA‐A*11 (carried by 42/441; 9.5% of patients) instead was an independent factor associated with a high risk of rapid disease recurrence (Fig. 2E,F; C‐index without HLA: 0.70, C‐index: 0.75 with HLA, S2C, Tables S4 and S5).